Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630262 | 0.74 | LMNA (0.45) | — | |
| SCHEMBL21855912 | 0.74 | BACE1 (0.36) | — | |
| SCHEMBL8304698 | 0.74 | CCR1 (0.36) | CYP1A2 | |
| SCHEMBL18300146 | 0.74 | — | — | |
| SCHEMBL21630296 | 0.73 | SCN5A (0.35) | GAAPOLB | |
| SCHEMBL21630297 | 0.73 | THRB (0.40) | GAA | |
| SCHEMBL21630306 | 0.73 | KDM4E (0.42) | CYP1A2 | |
| SCHEMBL21630286 | 0.72 | THRB (0.36) | — | |
| SCHEMBL315179 | 0.71 | POLB (0.33) | CLK1CYP1A2POLBTDP1 | |
| SCHEMBL491627 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | claimed |
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8106194-B2 | Pyrrolopyrimidine and pyrrolotriazine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20110137031-A1 | PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7557111-B2 | Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090111835-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| WO-2005066178-A1 | TRIAZA-CYCLOPENTA[CD]INDENE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066142-A2 | PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-21 | — | — | WO | disclosed |
| US-6852732-B2 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1467997-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004058767-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | WO | disclosed |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1299378-A4 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1299378-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | Taisho Pharmaceutical Co. Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002002549-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | NFE2L2 1131/4885GAA 1921/4885CYP11B2 754/4885 |
| US-20110137031-A1 | PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES | HRH2, CRHR1, HRH4 | NFE2L2 867/4885GAA 910/4885CYP11B2 2147/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | NFE2L2 1332/4885GAA 2461/4885CYP11B2 791/4885 |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | CRHR1, CRHR2, VIPR1 | NFE2L2 1291/4885GAA 3257/4885CYP11B2 311/4885 |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | CRHR1, CRHR2, AGTR1 | NFE2L2 1838/4885GAA 3380/4885CYP11B2 303/4885 |
| US-20090111835-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH3, HRH4 | NFE2L2 1398/4885GAA 698/4885CYP11B2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.